Option chain shows key data for ImmunityBio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ImmunityBio.

ImmunityBio (NASDAQ:IBRX) Stock, Option Chain

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Tesla Inc.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANNA

BTDR

CIFR

CURV

IBRX

KRNT

LION

NVDA

TSLA

Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Brinker

Intraday Update

CSGS

FFIV

LPRO

OKLO

PACK

SBUX

SYNA

TMUS

Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday

Quantum Computing

Equities

Mid Cap

ALHC

BPMC

COMP

HEES

IONQ

MSFT

OPCH

SEMR

Explore this week&#39;s top-performing mid-cap stocks, including H&amp;E Equipment Services&#39; impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush and Blueprint Medicines also experienced significant gains, impacting investment portfolios positively.

IonQ, H&amp;E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

ImmunityBio Inc

WIIM

Solidion Technology shares are trading lower on possible continued weakness after receiving a NASDAQ notice yesterday regarding its minimum market value of publicly held shares.

Guggenheim analyst Michael Morris maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $520 to $675.

Price Target

Analyst Ratings

SPOT

Guggenheim Maintains Buy on Spotify Technology, Raises Price Target to $675

AudioCodes Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) reported better-than-expected<a href="https://www.benzinga.com/quote/AUDC/earnings"> fourth-quarter earnings on Tuesday</a>.
The company posted quarterly earnings of 37 cents per share which beat the analyst consensus estimate of 23 cents per share. The company reported quarterly sales of $61.554 million which beat the analyst consensus estimate of $61.510 million.
&#8220;I am pleased to report solid fourth quarter performance, with healthy growth in key business lines, taking us further on our transformative evolution to a cloud software and services company,&#8221; said Shabtai Adlersberg, President and Chief Executive Officer of AudioCodes.
AudioCodes shares gained 5.3% to close at $10.66 on Tuesday.
These analysts made changes to their price targets on AudioCodes following earnings announcement.
<ul>
<li>Needham analyst Ryan Koontz maintained AudioCodes with a Buy and raised the price target from $11 to $12.5.</li>
<li>Barclays analyst Ryan Macwilliams maintained the stock with an Underweight rating and increased the price target from $9 to $10.</li>
</ul>
Considering buying AUDC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-1024x486.png" alt="" class="wp-image-767025" style="width:457px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-1024x486.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-300x142.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44-768x364.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074824/image-44.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Earnings

AUDC

AudioCodes Analysts Boost Their Forecasts Following Better-Than-Expected Earnings

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Outperform and raises the price target from $110 to $115.

Keefe, Bruyette & Woods Maintains Outperform on Axis Capital Holdings, Raises Price Target to $115

FirstService (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NASDAQ">FSV</a>) reported quarterly earnings of $1.34 per share which missed the analyst consensus estimate of $1.37 by 2.19 percent. This is a 20.72 percent increase over earnings of $1.11 per share from the same period last year. The company reported quarterly sales of $1.36 billion which beat the analyst consensus estimate of $1.33 billion by 2.89 percent. This is a 26.51 percent increase over sales of $1.08 billion the same period last year.

Earnings Beats

Earnings Misses

FirstService Q4 Adj  EPS $1.34 Misses $1.37 Estimate, Sales $1.36B Beat $1.33B Estimate

VLCN

Volcon shares are trading lower after the company announced a public offering of common stock and warrants.

The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">PayPal Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>)</h3>
<ul>
<li>On Feb. 4, PayPal reported fiscal fourth-quarter revenue growth of 4% year over year to $8.37 billion, topping the analyst consensus estimate of $8.26 billion. The company reported an adjusted EPS of $1.19, beating the analyst consensus estimate of $1.12. The company' stock fell around 12% over the past five days and has a<a href="https://www.benzinga.com/quote/PYPL"> 52-week low of $55.77</a>.</li>
<li>RSI Value: 21.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>PYPL Price Action: Shares of PayPal fell 13.2% to close at $77.72 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest PYPL <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35.png" alt="" class="wp-image-766680" style="width:665px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05044712/image-35-768x708.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>On Feb. 4, UBS Group reported fourth-quarter 2024 sales of $11.6 billion. That's up 7% year-over-year, beating the consensus of $11.2 billion. Underlying revenues upped 6% year-over-year to $11 billion, led by the performance of core businesses. The company's stock fell around 9% over the past five days and<a href="https://www.benzinga.com/quote/UBS"> has a 52-week low</a> of $26.00.</li>
<li>RSI Value: 29.4</li>
<li>UBS Price Action: Shares of UBS fell 7.2% to close at $32.41 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">UBS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36.png" alt="" class="wp-image-766685" style="width:654px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045048/image-36-768x698.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Virtus Investment Partners Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTS#NYSE">VRTS</a>)</h3>
<ul>
<li>On Jan. 31, Virtus Investment Partners posted upbeat quarterly results. The company's stock fell around 10% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/VRTS">low of $190.42</a>.</li>
<li>RSI Value: 25.3</li>
<li>VRTS Price Action: Shares of Virtus Investment Partners fell 1% to close at $194.56 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1">breakout in VRTS shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="875" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37.png" alt="" class="wp-image-766696" style="width:557px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37.png 875w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05045458/image-37-768x730.png 768w" sizes="(max-width: 875px) 100vw, 875px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Long Ideas

PYPL

VRTS

Top 3 Financial Stocks That May Rocket Higher This Quarter

RSVR

Reservoir Media shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY25 revenue guidance above estimates.

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Outperform and lowers the price target from $196 to $194.

Keefe, Bruyette & Woods Maintains Outperform on Apollo Global Management, Lowers Price Target to $194

Barclays analyst Tom O'Malley maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Equal-Weight and raises the price target from $105 to $115.

CRUS

Barclays Maintains Equal-Weight on Cirrus Logic, Raises Price Target to $115

Keybanc analyst Eric Gonzalez maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Overweight and lowers the price target from $66 to $64.

Keybanc Maintains Overweight on Chipotle Mexican Grill, Lowers Price Target to $64

The digital asset community is approaching the newfound embrace of crypto by the Trump administration with cautious optimism, after a Tuesday press conference led by David Sacks, <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43477333/crypto-czar-sacks-says-potential-bitcoin-reserve-to-be-one-of-crypto-committees-first-priorities">the designated &#8220;Crypto Czar.&#8221;</a>
What Happened: While the rhetoric surrounding innovation and regulatory clarity has been well-received, industry experts are now scrutinizing the actual plans and questioning whether the proposed changes will truly benefit the broader crypto ecosystem.
Experts see this as a critical juncture, but they also caution against potential pitfalls.
The formation of a bipartisan working group was a central announcement, signaling an effort to harmonize regulatory efforts across Congress and the executive branch. 
The initiative aims to create a framework for stablecoins and market structure legislation, which could have profound implications for the global financial system.
Speaking with Benzinga, Todd Ruoff, CEO of Autonomys, pointed out the measured approach outlined by Sacks. 
"Lawmakers are ‘exploring the possibilities,'" Ruoff said, noting that the emphasis was on forming committees, educating Congress, and determining the feasibility of frameworks. 
While these early steps are crucial, Ruoff highlighted the economic implications of stablecoin legislation. 
"Higher demand for T-bills would cause their prices to go up, which in turn pushes yields down and lowers interest rates," he said. 
This approach could tie stablecoin adoption directly to the strength of the U.S. dollar and the Treasury market.
Notably, stablecoins could serve as both a technological and economic tool. 
By linking their reserve requirements to U.S. Treasuries, stablecoins could provide a new channel for Treasury demand, reinforcing the dollar's dominance. 
However, this integration would require careful calibration to avoid market distortions, especially given the size of the stablecoin market, which currently exceeds $227 billion.
Paul Neuner, founder of Telcoin, told Benzinga the announcement marks a turning point for crypto in the U.S., where regulators are no longer trying to suppress innovation but are instead working to position the country at the center of digital assets.
He drew parallels to the regulatory evolution seen during the rise of Web 2.0, emphasizing that crypto regulation should focus on gateways like digital asset banks rather than attempting to control decentralized networks.
The media briefing also highlights a shift in regulatory thinking. 
Instead of enforcing broad restrictions, the focus on key entry points like digital asset banks suggests a pragmatic approach. 
This strategy could ensure compliance without stifling innovation, fostering an environment where blockchain-based financial services can thrive alongside traditional systems.
Joao Reginatto, Chief Strategy Officer at M^0, praised the administration's progress on stablecoin clarity. 
"The pace with which the Trump administration is moving through the phases is welcomed by the sector," Reginatto told Benzinga. 
He highlighted the balance between federal oversight and flexibility for state regulators, calling it a "reasonable approach."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43475386/exclusive-anthony-scaramucci-warns-donald-trumps-crypto-promises-may-be-a-mirage">EXCLUSIVE: Anthony Scaramucci Warns Donald Trump&#8217;s Crypto Promises May Be A &#8216;Mirage&#8217;</a>
Why It Matters: Experts point to a potential decentralization of stablecoin oversight, with state regulators playing a significant role.
This could align with the broader U.S. tradition of federalism while addressing the specific needs of different jurisdictions. 
However, it also raises questions about uniformity and consistency, particularly for large-scale issuers operating across states.
Speaking with Benzinga, Laurenth Alba, Head of Business Development at Rome Protocol, sees the bipartisan effort as a clear sign of crypto's growing importance and said the bipartisan working group and Senate stablecoin bill suggest that crypto is now a national economic and geopolitical priority, not just a speculative asset class.
However, he warned that overregulation could drive users toward decentralized alternatives. "The real threat to dollar hegemony isn't crypto—it's bad policy that pushes financial innovation beyond U.S. control."
There is a delicate balance regulators must strike. 
While integrating stablecoins into the financial system could bolster the dollar's dominance, excessive control risks alienating innovators and users. 
This could create an unintended shift toward decentralized stablecoins or alternative financial systems, eroding the very dominance the U.S. seeks to strengthen.
Alice Liu, Research Lead at CoinMarketCap, acknowledged the administration's recognition of past regulatory missteps. 
"David Sacks and team acknowledged past policies have been inconsistent and, at times, arbitrary—pushing crypto innovation offshore," Liu told Benzinga. 
She emphasized that the focus on stablecoins is a logical first step, given their role in global financial markets. 
However, Liu noted a missed opportunity in the absence of a clearer plan for Bitcoin reserves, which some stakeholders had anticipated.
While stablecoin regulation is critical, Bitcoin remains central to the crypto ecosystem. 
A well-defined policy on Bitcoin could provide additional clarity, particularly as other nations explore BTC as a reserve asset.
Dave Sedacca, Head of Finance at Parity Technologies, viewed the announcement as a positive step but noted market expectations for more impactful measures. 
"The emphasis on reinforcing the dollar from a digital perspective was encouraging, and it will be intriguing to see how the BRICS nations respond," Sedacca said.
As BRICS nations explore alternatives to the dollar, the U.S.'s focus on digital assets could serve as a counterbalance. 
However, this will require swift and effective action to avoid falling <a href="https://www.benzinga.com/markets/cryptocurrency/23/07/33333534/brics-emerges-as-new-global-powerhouse-us-dollar-faces-uncertain-future">behind in the global financial race.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43473182/could-the-trump-established-sovereign-wealth-fund-invest-in-bitcoin-nvidia-tiktok">Could The Trump-Established Sovereign Wealth Fund Invest In Bitcoin, Nvidia, TikTok?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

EXCLUSIVE: 'Crypto Czar' Charm Offensive Welcomed, But Experts Wonder: Will US Policy Deliver?

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Outperform and raises the price target from $411 to $414.

Keefe, Bruyette & Woods Maintains Outperform on Aon, Raises Price Target to $414

Barclays analyst Jeffrey Bernstein maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Equal-Weight and lowers the price target from $63 to $60.

Barclays Maintains Equal-Weight on Chipotle Mexican Grill, Lowers Price Target to $60

On Wednesday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) reported sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (79.73 billion Danish Kroner).
Sales increased by 30% in Danish kroner and at CER compared to 2023.
GLP-1 diabetes sales increased by 12% at CER to 42.17 billion Danish kroner, and Obesity care sales increased by 91% at <a target="_blank" href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss" rel="noreferrer noopener">CER to 21.41 billion Danish kroner</a>.
Ozempic <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915255" rel="noreferrer noopener">sales</a> increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43475491/novo-nordisk-stock-q4-earnings-analysts-68-upside" rel="noreferrer noopener">to 19.87 billion Danish kroner</a>.
Insulin sales increased 36% to 15.9 billion Danish kroner, and Rare disease sales increased 25% at CER to 5.71 billion Danish kroner.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
The Danish pharmaceutical giant&#8217;s net profit increased by 29% to 28.23 billion kroner, with EPS of 6.34 Danish kroner, up 29%, beating the consensus of 5.82 Danish kroner. In USD terms, EPS of $0.91 beat $0.83 consensus.
In its earnings release, Novo Nordisk outlined its plans to conduct a new phase 3 trial in 2025 to further explore <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">CagriSema&#8217;s weight-loss potential</a>.
The results from the second pivotal phase 3 trial, REDEFINE 2, of CagriSema in adults with type 2 diabetes and either obesity or overweight are expected during the first quarter of 2025
To secure <a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/365675dd-10f3-4293-9aec-ede9f63375c6" rel="noreferrer noopener">supply</a> chain readiness, the company now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026.
Guidance: Novo Nordisk expects sales growth of between 16% and 24% in constant exchange rates this year, lower than the 26% achieved in 2024.
&#8220;In 2025, we will continue our focus on commercial execution, on the progression of our early and late-stage R&amp;D pipeline and on the expansion of our production capacity,&#8221; Chief Executive Lars Fruergaard Jorgensen said.
The company expects 2025 operating profit growth of 19% to 27% in constant exchange rates.
Novo Nordisk adds that the outlook reflects expected continued periodic supply constraints and related drug shortage notifications across several products and geographies. Novo Nordisk is investing in internal and external capacity to increase supply in the short and long term.
Price Action: At last check on Wednesday, NVO stock was up 3.09% at $85.17 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43475015/spotifys-strong-subscriber-growth-and-rising-margins-keep-analysts-bullish" target="_blank" rel="noreferrer noopener">Spotify Is Still One Of Top 4 Best Ideas For 2025: Analyst</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Guidance

Health Care

General

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Group shares are trading lower after the company reported a year-over-year decrease in 9-month financial results.

Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) reported better-than-expected fourth-quarter financial results after Tuesday&#8217;s closing bell.
Snap reported quarterly earnings of 16 cents per share, which beat the analyst consensus estimate of 14 cents. Quarterly revenue came in at $1.55 billion, which beat the analyst consensus estimate of $1.54 billion and is an increase over revenue of $1.36 billion from the same period last year.
Snapchat had 453 million daily active users in the fourth quarter, up 9% year-over-year.
"In 2024 we made significant progress on our core priorities of growing our community and improving depth of engagement, driving top-line revenue growth and diversifying our revenue sources, while building toward our long-term vision for augmented reality," said Evan Spiegel, Snap CEO
Snap shares gained 3.9% to close at $11.60 on Tuesday.
These analysts made changes to their price targets on Snap following earnings announcement.
<ul>
<li>Wells Fargo analyst Ken Gawrelski downgraded Snap from Overweight to Equal-Weight and lowered the price target from $15 to $11.</li>
<li>B of A Securities analyst Justin Post maintained the stock with a Neutral and raised the price target from $14 to $14.5.</li>
</ul>
Considering buying SNAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074230/image-43-1024x586.png" alt="" class="wp-image-767005" style="width:559px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074230/image-43-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074230/image-43-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074230/image-43-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05074230/image-43.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

SNAP

These Analysts Revise Their Forecasts On Snap After Q4 Results

Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) will release its third-quarter financial results, after the closing <a href="https://www.benzinga.com/quote/ARM/earnings">bell, on Wednesday, Feb. 5, 2025.</a>
Analysts expect the UK-based company to report quarterly earnings at 34 cents per share, up from 29 cents per share in the year-ago period. Arm Holdings projects quarterly revenue of $948 million, compared to $824 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
British chip designer Arm's Chinese venture is eyeing Chen Feng, a former Rockchip Electronics Co. officer, as its CEO, taking over from co-CEOs Liu Renchen and Eric Chen.
Arm Holdings shares gained 4.2% to close at $162.20 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Blayne Curtis maintained an Overweight rating and raised the price target from $145 to $155 on Jan. 17, 2025. This analyst has an accuracy rate of 74%.</li>
<li>UBS analyst Timothy Arcuri initiated coverage on the stock with a Buy rating and a price target of $160 on Nov. 25, 2024. This analyst has an accuracy rate of 77%.</li>
<li>Loop Capital analyst Ananda Baruah maintained a Buy rating and increased the price target from $130 to $180 on Nov. 11, 2024. This analyst has an accuracy rate of 75%.</li>
<li>JP Morgan analyst Harlan Sur maintained an Overweight rating and raised the price target from $140 to $160 on Nov. 7, 2024. This analyst has an accuracy rate of 80%.</li>
<li>Goldman Sachs analyst Toshiya Hari maintained a Buy rating and raised the price target from $144 to $159 on Nov. 7, 2024. This analyst has an accuracy rate of 81%.</li>
</ul>
Considering buying ARM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="498" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05022643/image-33-1024x498.png" alt="" class="wp-image-766352" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05022643/image-33-1024x498.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05022643/image-33-300x146.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05022643/image-33-768x373.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05022643/image-33.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Top Wall Street Forecasters Revamp Arm Holdings Price Expectations Ahead Of Q3 Earnings

Barclays analyst Betty Jiang maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and lowers the price target from $174 to $171.

Barclays Maintains Overweight on Chevron, Lowers Price Target to $171

AMTM

Amentum shares are trading higher after the company reported better-than-expected Q1 financial results.

Press Releases

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Comments

ImmunityBio

ImmunityBio (IBRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga